Hoboken, NJ, December 14, 2015- Primary Immune Deficiency (PID) Patients and Investigators Needed for Post Marketing, Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, Comparing the Occurrence of Adverse Drug Reactions Between Octagam 5% and other Marketed IVIG Infusion Treatments.

You may be eligible for this study if:
- You are a patient 18 years and older
- have a confirmed diagnosis of PID
- have been receiving IVIG infusions of Octagam 5% every 3-4 weeks for a period of at least 60 days prior to enrollment
- do not have a history of Thromboembolic events (ischemic stroke, transient ischemic attack, cerebral infarction, cerebrovascular accident, cerebral thrombosis, embolic infarctions (acute), myocardial infarction, deep vein thrombosis, pulmonary embolism, or venous thrombosis) within the previous 24 months.

If your physician is not participating in this study, he or she may be able to refer you to a participating physician and you would continue your infusions at your local physician’s office or at home.

If you would like more information regarding this study, please contact: michael.eppolito@octapharma.com or melody.baker@octapharma.com. You may also visit www.clintrials.gov for additional study information.

If you are a physician wishing to participate or obtain additional information regarding this study, please contact: Michael.eppolito@octapharma.com or melody.baker@octapharma.com.